ALPHA EMITTER MARKET ANALYSIS

Alpha Emitter Market, by Type of Radionuclide (Radium (Ra-223), Actinium (Ac-225), Lead (Pb-212), Astatine-211, Bismuth-213 and Others), by Source (Natural Sources (Uranium-238 and Radium-226) Artificially Produced Sources (Plutonium, Americium, Curium and Californium), by Application (Bone Metastases, Prostate Cancer, Neuroendocrine Tumors, Ovarian Cancer and Others), by End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)-

Published In : Jul 2023
Code : CMI5534
Pages :244
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Global Alpha Emitter Market - Driver

Increasing Prevalence of Cancer Worldwide

Increasing prevalence of different types of cancer such as breast cancer, prostate cancer, neuroendocrine tumors, ovarian cancer, and others is expected to drive the growth of global alpha emitter market over the forecast period. For instance according to data published by the World Health Organization, in February 2022, cancer is a prominent cause of death worldwide, accounting for about 10 million fatalities in 2020, or nearly one in six deaths.

Increasing Research and Development Activities

Increasing research and development by key market players for the discovery of new treatment such as alpha radioligand therapy to treat cancer is expected to drive the global alpha emitter market over the forecast period. For instance, on January 4, 2023, Orano Med, a pharmaceutical company, announced that the 212Pb-GRPR, an alpha radioligand therapy with lead-212, for patients with solid tumors that express the gastrin-releasing peptide receptor, has dosed its first patient in a Phase 1 clinical trial. 212Pb-GRPR is the targeted alpha therapy aiming gastrin-releasing peptide receptor, a protein found on the surface of cells that is expressed in prostate cancer, lung cancer, breast cancer and other solid tumors

Global Alpha Emitter Market: Restraint

Drawbacks Associated with Targeted Alpha Particle Therapy

Radiation therapy kills cancer cells or slows their growth of cells by damaging their DNA. Radiotherapy is a cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors. Radiation therapy can have certain common side effects, however these effects differ from person to person, and this is due to the fact that side effects might vary depending on the kind of cancer, where it is located, radiation therapy dose, patient's overall health, and other factors. Increasing side effects of radiation therapy is expected to hamper the growth of global alpha emitter market over the forecast period. For instance, according to data published in January 2022, by National Cancer Institute, U.S., following are the possible side effects of Radiotherapy: fatigue, taste change, skin color change, diarrhea, hair loss, urinary and bladder problems, fertility problems in men and others.